AstraZeneca PLC (AZN)vsCharming Medical Limited Class A Ordinary Shares (MCTA)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
MCTA
Charming Medical Limited Class A Ordinary Shares
$29.36
0.00%
HEALTHCARE · Cap: $504.26M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 1083006% more annual revenue ($58.74B vs $5.42M). AZN leads profitability with a 17.4% profit margin vs 12.1%. AZN trades at a lower P/E of 27.9x. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
MCTA
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Intrinsic value data unavailable for MCTA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Earnings expanding 81.0% YoY
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Premium valuation, high expectations priced in
Trading at 1467.8x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : MCTA
The strongest argument for MCTA centers on EPS Growth.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : MCTA
The primary concerns for MCTA are Market Cap, Return on Equity, P/E Ratio. A P/E of 419.4x leaves little room for execution misses.
Key Dynamics to Monitor
AZN profiles as a value stock while MCTA is a declining play — different risk/reward profiles.
AZN is growing revenue faster at 4.1% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (64/100 vs 27/100), backed by strong 17.4% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Charming Medical Limited Class A Ordinary Shares
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Charming Medical Limited, engage in the provision of beauty, wellness, and postpartum services under the Beauty Lab brand name in Hong Kong. The company is headquartered in Causeway Bay, Hong Kong.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?